TABLE 1.
Baseline characteristics of losartan and hydrochlorothiazide group vs. losartan and amlodipine group
| Losartan and HCTZ (n = 72) | Losartan and amlodipine (n = 70) | P | |
| Age (years) | 59.3 ± 11.7 | 58.4 ± 12.9 | 0.6633 |
| Female (%) | 36.9% | 22.9% | 0.0655 |
| BMI (kg/m2) | 25.9 ± 3.0 | 25.9 ± 2.9 | 0.9758 |
| Drinking | 56.2% | 45.7% | 0.2142 |
| Smoking | 24.6% | 18.5% | 0.3808 |
| Waist circumference (cm) | 89.9 ± 9.0 | 89.5 ± 8.5 | 0.7849 |
| Clinic SBP (mmHg) | 153.7 ± 9.5 | 153.9 ± 11.0 | 0.5713 |
| Clinic DBP (mmHg) | 92.5 ± 8.4 | 92.9 ± 8.8 | 0.8778 |
| Heart rate (bpm) | 71.2 ± 10.5 | 69.4 ± 9.6 | 0.2530 |
| Fasting blood glucose (mg/dl) | 109.7 ± 17.0 | 105.4 ± 18.3 | 0.1576 |
| Creatinine (mg/dl) | 0.9 ± 0.2 | 0.9 ± 0.2 | 0.1482 |
| Uric acid (mg/dl) | 5.4 ± 1.3 | 5.8 ± 1.2 | 0.0349 |
| Total cholesterol (mg/dl) | 187.2 ± 38.6 | 182.1 ± 36.5 | 0.4123 |
| Haemoglobin A1c (%) | 5.8 ± 0.7 | 5.8 ± 0.7 | 0.581 |
| Sodium (mEq/l) | 141.0 ± 2.2 | 140.8 ± 2.0 | 0.5204 |
| Potassium (mEq/l) | 4.4 ± 0.3 | 4.4 ± 0.3 | 0.4793 |
| Albumin creatinine ratio (mg/g) | 33.3 ± 91.3 | 24.9 ± 47.0 | 0.4986 |
| Brachial SBP, 24 h (mmHg) | 135.7 ± 10.4 | 137.2 ± 13.0 | 0.4619 |
| Brachial SBP, daytime (mmHg) | 141.0 ± 11.0 | 141.2 ± 13.9 | 0.9289 |
| Brachial SBP, night-time (mmHg) | 125.3 ± 13.7 | 129.7 ± 14.1 | 0.0631 |
| Brachial DBP, 24 h (mmHg) | 86.8 ± 9.4 | 87.0 ± 10.1 | 0.8943 |
| Brachial DBP, daytime (mmHg) | 91.2 ± 9.7 | 90.2 ± 10.3 | 0.5276 |
| Brachial DBP, night-time (mmHg) | 78.1 ± 11.6 | 81.0 ± 11.5 | 0.1355 |
| Heart rate, 24 h (bpm) | 71.6 ± 9.7 | 68.8 ± 8.5 | 0.0697 |
| Heart rate, daytime (bpm) | 75.7 ± 10.8 | 72.5 ± 8.9 | 0.0535 |
| Heart rate, night-time (bpm) | 63.8 ± 9.2 | 62.1 ± 9.8 | 0.2851 |
| Nocturnal dipping (mmHg) | 10.9 ± 9.2 | 7.9 ± 7.5 | 0.0364 |
| Dipper (%) | 58.9% | 40.0% | 0.0238 |
| Central SBP, 24 h (mmHg) | 125.4 ± 9.6 | 127.4 ± 12.4 | 0.2790 |
| Central SBP, daytime (mmHg) | 129.9 ± 10.1 | 130.4 ± 13.5 | 0.7727 |
| Central SBP, night-time (mmHg) | 116.7 ± 12.7 | 121.8 ± 13.6 | 0.022 |
| Ambulatory PPA, 24-h | 1.27 ± 0.08 | 1.25 ± 0.06 | 0.1032 |
| Ambulatory PPA, daytime | 1.29 ± 0.08 | 1.27 ± 0.07 | 0.1088 |
| Ambulatory PPA, night-time | 1.23 ± 0.11 | 1.22 ± 0.11 | 0.6368 |
| Ambulatory AIx75, 24-h (%) | 23.9 ± 9.5 | 22.3 ± 9.4 | 0.3173 |
| Ambulatory AIx75, daytime (%) | 24.4 ± 9.3 | 22.0 ± 8.7 | 0.123 |
| Ambulatory AIx75, night-time (%) | 23.2 ± 12.2 | 22.8 ± 12.6 | 0.8457 |
| Ambulatory cfPWV, 24-h (m/s) | 8.8 ± 1.6 | 9.0 ± 1.8 | 0.7202 |
| Ambulatory cfPWV, daytime (m/s) | 9.0 ± 1.6 | 9.1 ± 1.8 | 0.8345 |
| Ambulatory cfPWV, night-time (m/s) | 8.5 ± 1.7 | 8.7 ± 1.8 | 0.5051 |
AIx75, augmentation index calibrated for the assumed ambulatory heart rate of 75 beats per minute; cfPWV, carotid femoral pulse wave velocity; HCTZ, dihydrochlorothiazide; PPA, pulse pressure amplification.